| Symbol | Company | Owner | Relationship | Date | Transaction | Cost | # Shares | Value ($) | Total Shares | Filing | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | Kevin Michael Krause | Chief Strategy Officer | Jan 09, 2024 | Option/RSU Exercise | $4.59 | 7,417 | 34,015 | 9,331 | Jan 11, 2024, 07:59 PM | |
| ANTX | AN2 Therapeutics, Inc. | Kevin Michael Krause | Chief Strategy Officer | Jan 09, 2024 | Sale | $20.14 | 7,417 | 149,367 | 1,914 | Jan 11, 2024, 07:59 PM | |
| ANTX | AN2 Therapeutics, Inc. | Kevin Michael Krause | Chief Strategy Officer | Jan 02, 2024 | Option/RSU Exercise | $0.42 | 2,583 | 1,085 | 4,497 | Jan 04, 2024, 06:06 PM | |
| ANTX | AN2 Therapeutics, Inc. | Kevin Michael Krause | Chief Strategy Officer | Jan 02, 2024 | Sale | $20.12 | 2,583 | 51,967 | 1,914 | Jan 04, 2024, 06:06 PM |
- Subscribe
- Premium
- C-Suite
- Insiders
- M&A
- Gurus
- Spinoffs
- Buybacks
- More